Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

REVISITING THE CHOLINERGIC HYPOTHESIS IN ALZHEIMER’S DISEASE: EMERGING EVIDENCE FROM TRANSLATIONAL AND CLINICAL RESEARCH
Harald Hampel, M.‐Marsel Mesulam, A. Claudio Cuello, et al.
The Journal of Prevention of Alzheimer s Disease (2018), pp. 1-14
Closed Access | Times Cited: 267

Showing 1-25 of 267 citing articles:

A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics
Richard Nii Lante Lamptey, Bivek Chaulagain, Riddhi Trivedi, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1851-1851
Open Access | Times Cited: 470
Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis
Łucja Justyna Walczak-Nowicka, Mariola Herbet
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9290-9290
Open Access | Times Cited: 166
APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases
Rosalía Fernández‐Calle, Sabine C. Konings, Javier Frontiñán-Rubio, et al.
Molecular Neurodegeneration (2022) Vol. 17, Iss. 1
Open Access | Times Cited: 142
Entorhinal cortex dysfunction in Alzheimer's disease
Kei M. Igarashi
Trends in Neurosciences (2022) Vol. 46, Iss. 2, pp. 124-136
Open Access | Times Cited: 123
The Biology and Pathobiology of Glutamatergic, Cholinergic, and Dopaminergic Signaling in the Aging Brain
Anna Gąsiorowska, Małgorzata Wydrych, Patrycja Drapich, et al.
Frontiers in Aging Neuroscience (2021) Vol. 13
Open Access | Times Cited: 116
The Cholinergic System, the Adrenergic System and the Neuropathology of Alzheimer’s Disease
Rola A. Bekdash
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 3, pp. 1273-1273
Open Access | Times Cited: 115
Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer’s disease: Limitations, and current and future perspectives
Kehinde D. Fasae, Amos O. Abolaji, Tolulope R. Faloye, et al.
Journal of Trace Elements in Medicine and Biology (2021) Vol. 67, pp. 126779-126779
Open Access | Times Cited: 108
Piperidine Derivatives: Recent Advances in Synthesis and Pharmacological Applications
Nikita A. Frolov, A. N. Vereshchagin
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2937-2937
Open Access | Times Cited: 82
Current and future therapeutic strategies for Alzheimer’s disease: an overview of drug development bottlenecks
Yong Peng, Hong Jin, Ya-hui Xue, et al.
Frontiers in Aging Neuroscience (2023) Vol. 15
Open Access | Times Cited: 69
Kaempferol, a potential neuroprotective agent in neurodegenerative diseases: From chemistry to medicine
Shuai Jin, Lijuan Zhang, Lin Wang
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115215-115215
Open Access | Times Cited: 58
Review of Pharmacotherapeutic Targets in Alzheimer’s Disease and Its Management Using Traditional Medicinal Plants
Prabhash Nath Tripathi, Ankit Lodhi, Sachchida Nand, et al.
Degenerative Neurological and Neuromuscular Disease (2024) Vol. Volume 14, pp. 47-74
Open Access | Times Cited: 53
Understanding of Alzheimer's Disease Pathophysiology for Therapeutic Implications of Natural Products as Neuroprotective Agents
Sneh Prabha, Arunabh Choudhury, Asimul Islam, et al.
Ageing Research Reviews (2025), pp. 102680-102680
Closed Access | Times Cited: 2
Innovative Therapy for Alzheimer’s Disease-With Focus on Biodelivery of NGF
Sumonto Mitra, Homira Behbahani, Maria Eriksdotter
Frontiers in Neuroscience (2019) Vol. 13
Open Access | Times Cited: 138
From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology
Claudia Albertini, Alessandra Salerno, Pedro de Sena Murteira Pinheiro, et al.
Medicinal Research Reviews (2020) Vol. 41, Iss. 5, pp. 2606-2633
Closed Access | Times Cited: 129
Neurobiochemical Cross-talk Between COVID-19 and Alzheimer’s Disease
Mohammad Azizur Rahman, Kamrul Islam, Saidur Rahman, et al.
Molecular Neurobiology (2020) Vol. 58, Iss. 3, pp. 1017-1023
Open Access | Times Cited: 112
Nanomaterials for the treatment and diagnosis of Alzheimer's disease: An overview
Muhammad Bilal, Mahmood Barani, Fakhara Sabir, et al.
NanoImpact (2020) Vol. 20, pp. 100251-100251
Closed Access | Times Cited: 102
Cholinergic Modulation of Glial Function During Aging and Chronic Neuroinflammation
Rashmi Gamage, Ingrid Wagnon, Ilaria Rossetti, et al.
Frontiers in Cellular Neuroscience (2020) Vol. 14
Open Access | Times Cited: 92
Amyloid-β, tau, and the cholinergic system in Alzheimer’s disease: seeking direction in a tangle of clues
Alireza Majdi, Saeed Sadigh‐Eteghad, Sepideh Rahigh Aghsan, et al.
Reviews in the Neurosciences (2020) Vol. 31, Iss. 4, pp. 391-413
Closed Access | Times Cited: 87
The Alzheimer Precision Medicine Initiative
Harald Hampel, Andrea Vergallo, George Perry, et al.
Journal of Alzheimer s Disease (2019) Vol. 68, Iss. 1, pp. 1-24
Closed Access | Times Cited: 85
Nanocarrier mediated drug delivery as an impeccable therapeutic approach against Alzheimer’s disease
Rajeev Taliyan, Violina Kakoty, K C Sarathlal, et al.
Journal of Controlled Release (2022) Vol. 343, pp. 528-550
Closed Access | Times Cited: 45
Natural Therapeutics in Aid of Treating Alzheimer’s Disease: A Green Gateway Toward Ending Quest for Treating Neurological Disorders
Basharat Ahmad Bhat, Abdullah Almilaibary, Rakeeb Ahmad Mir, et al.
Frontiers in Neuroscience (2022) Vol. 16
Open Access | Times Cited: 41
Noradrenergic and cholinergic systems take centre stage in neuropsychiatric diseases of ageing
Isabella F. Orlando, James M. Shine, Trevor W. Robbins, et al.
Neuroscience & Biobehavioral Reviews (2023) Vol. 149, pp. 105167-105167
Open Access | Times Cited: 33
New perspectives on the basal forebrain cholinergic system in Alzheimer’s disease
Anne S. Berry, Theresa M. Harrison
Neuroscience & Biobehavioral Reviews (2023) Vol. 150, pp. 105192-105192
Open Access | Times Cited: 32
A Comparative Study of Green and Chemical Cerium Oxide Nanoparticles (CeO2-NPs): From Synthesis, Characterization, and Electrochemical Analysis to Multifaceted Biomedical Applications
Muhammad Aslam Khan, Muhammad Aamir Ramzan Siddique, Muhammad Munir Sajid, et al.
BioNanoScience (2023) Vol. 13, Iss. 2, pp. 667-685
Closed Access | Times Cited: 23
Controversial Past, Splendid Present, Unpredictable Future: A Brief Review of Alzheimer Disease History
Félix Bermejo‐Pareja, Teodoro del Ser
Journal of Clinical Medicine (2024) Vol. 13, Iss. 2, pp. 536-536
Open Access | Times Cited: 10
Page 1 - Next Page

Scroll to top